Ann: Half Year Accounts, page-4

got to be very patient with this one.. under DFA ( not guaranteed but would imagine they will secure ) they have plenty more funding so no concern there but the continued difficulty in conducting this global phase 3 trial is just extraordinary

admittedly the confluence of events COVID, Ukraine War amongst other things have certainly disrupted organisations that depend on global supply chains + members of the public willing and able under all of their own struggles etc to enrol in trials

it's in the bottom draw.. not selling but if it really tanks in the interim I'll add a few more.. this is the way of the biotech

GLTAH